Invests in listed companies globally, taking leading minority positions in healthcare, financial services, IT, and fintech sectors. Now — the numbers.
This is an established company with proven profits.
An average decline of 5% a year over the last 3 years — the most striking risk in this picture.
The market pays 7.8× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
The stock trades below its recent peak — about 9% off the top. A pullback, not a collapse.
The net profit margin is 71% — the profit kept from each dollar of revenue is the company’s cushion in hard quarters.
It pays out $0.59 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales fell about 5% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.